Exonate's lead program molecules act via a novel mechanism of action to inhibit pathological blood vessels and reduce the formation of pathological Vascular Endothelial Growth Factor without inhibiting beneficial, non-pathological VEGF. The company aims to improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. Exonate is an early stage biopharmaceutical company with drug discovery programmes in ophthalmology, oncology and pain.